

(12) International Application Status Report

Received at International Bureau: 09 December 2019 (09.12.2019)

Information valid as of: 14 February 2020 (14.02.2020)

Report generated on: 24 September 2020 (24.09.2020)

(10) Publication number:

WO2020/112655

(43) Publication date:

04 June 2020 (04.06.2020)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2019/063044

(22) Filing Date:

25 November 2019 (25.11.2019)

(25) Filing language:

English (EN)

(31) Priority number(s):

62/771,529 (US)

(31) Priority date(s):

26 November 2018 (26.11.2018)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 31/155 (2006.01); **A61K 31/337** (2006.01); **A61K 31/496** (2006.01)

(71) Applicant(s):

AIVIVA BIOPHARMA, INC. [US/US]; 848 N. Rainbow Blvd., Suite 2654 Las Vegas, NV 89107 (US) *(for all designated states)*

(72) Inventor(s):

DING, Shulin; 14402 Friendlywood Road Silver Spring, MD 20905 (US)

TANG-LIU, Diane; 848 N. Rainbow Blvd., Suite 2654 Las Vegas, NV 89107 (US)

(74) Agent(s):

JOHNSON, Brent, A.; Maschoff Brennan 100 Spectrum Center Drive, Suite 1200 Irvine, CA 92618 (US)

(54) Title (EN): PHARMACEUTICAL BIODISSOLVABLE GELS FOR DRUG DELIVERY

(54) Title (FR): GELS BIOSOLUBLES PHARMACEUTIQUES POUR L'ADMINISTRATION DE MÉDICAMENT

(57) Abstract:

(EN): This disclosure relates to a pharmaceutical bio-dissolvable/bioerodible aqueous gel system optionally comprising an active pharmaceutical ingredient, wherein the pharmaceutical composition makes a transition from liquid to gel near the body temperature of a mammal. These compositions may include a reversibly-gelling material, such as methylcellulose and a rheology modifier such as citrate.

(FR): La présente invention concerne un système de gel aqueux biosoluble/bioérodable pharmaceutique comprenant éventuellement un principe pharmaceutique actif, la composition pharmaceutique réalisant une transition de liquide à gel proche de la température corporelle d'un mammifère. Ces compositions peuvent comprendre un matériau à gélification réversible, tel que la méthylcellulose, et un modificateur de rhéologie tel que le citrate.

International search report:

Received at International Bureau: 13 February 2020 (13.02.2020) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM